JPRN-UMIN000012202CompletedPhase 2
Phase 2 study of efficacy and safety of fosaprepitant in patients with solid tumor receiving highly emetogenic chemotherapy - Phase 2 study of efficacy and safety of fosaprepitant for highly emetogenic chemotherapy
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Kyushu University
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) patients who have need of administration of aprepitant over 4 days 2) with allergy to aprepitant 3) Possibly pregnant, or breast feeding woman 4) with Acute myocardial infaction in 6 months or with unstable ungina, congestive heart failure (NYHA >= class3), other serious cardiac disoder 5) patients with symptomatic brain metastasis 6) with hypercalcemia requiring an urgent treatment 7) patients taking medicines interacted with CYP3A4 or CYP2C9 8) with uncontrolled diabetes mellitus 9) with pleural effusion, ascitis and pericardial effusion 10) patients who are disqualified by attending physicians
Investigators
Similar Trials
Completed
Not Applicable
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaMultiple MyelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30
Not yet recruiting
Not Applicable
Tab Posaconazole study in patients with cancersCTRI/2021/03/032019Christian Medical College
Active, not recruiting
Not Applicable
Study to learn if 200mg test drug (Fostamatinib) helps people with Large B-Cell Lymphoma, a type of blood cancerDiffuse Large B-cell LymphomaMedDRA version: 16.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864EUCTR2011-005371-16-GBRigel Pharmaceuticals, Inc.60
Not yet recruiting
Phase 2
Phase II study evaluating the efficacy of Pasireotide long-acting release (LAR; SOM230) dose escalation in patients with refractory non-functional gastroenteropancreatic neuroendocrine tumors (GEP NETs).Gastro-entero-pancreatic neuroendocrine tumoursCancer - Neuroendocrine tumour (NET)ACTRN12615001328561Peter MacCallum Cancer Centre30
Completed
Phase 2
Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC)on-small cell lung cancerJPRN-UMIN000020370Saitama Lung Cancer Research Group40